A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD)

被引:41
作者
Savarino, Edoardo [1 ]
Zentilin, Patrizia [2 ]
Marabotto, Elisa [2 ]
Bodini, Giorgia [2 ]
Della Coletta, Marco [1 ]
Frazzoni, Marzio [3 ]
de Bortoli, Nicola [4 ]
Martinucci, Irene [4 ]
Tolone, Salvatore [5 ]
Pellegatta, Gaia [2 ]
Savarino, Vincenzo [2 ]
机构
[1] Univ Padua, Dept Surg Oncol & Gastroenterol, Gastrointestinal Unit, Via Giustiniani 2, I-35128 Padua, Italy
[2] Univ Genoa, Dept Internal Med & Med Specialties, Gastrointestinal Unit, Genoa, Italy
[3] Baggiovara Hosp, Digest Pathophysiol Unit, Modena, Italy
[4] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy
[5] Second Univ Napoli, Dept Surg, Gen & Bariatr Surg Unit, Naples, Italy
关键词
Antidepressants; GERD; medical therapy; mucosa protective medications; PPIs; prokinetics; reflux inhibitors; PROTON-PUMP INHIBITOR; RANDOMIZED CLINICAL-TRIAL; MULTICHANNEL INTRALUMINAL IMPEDANCE; ESOPHAGEAL MUCOSAL INTEGRITY; COMPETITIVE ACID BLOCKER; IRRITABLE-BOWEL-SYNDROME; FUNCTIONAL HEARTBURN; EROSIVE ESOPHAGITIS; DOUBLE-BLIND; PATHOPHYSIOLOGICAL CHARACTERISTICS;
D O I
10.1080/14656566.2017.1361407
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Medical therapy of gastroesophageal reflux disease (GERD) is based on the use of proton pump inhibitors (PPIs) as first choice treatment. Despite their effectiveness, about 20-30% of patients report an inadequate response and alternative drugs are required.Areas covered: This review provides an overview of current pharmacotherapy for treating GERD by showing the results of PPIs, reflux inhibitors, antidepressants and mucosa protective medications.Expert opinion: Medical therapy of GERD does not definitely cure the disease, because even PPIs are not able to change the key factors responsible for it. However, they remain the mainstay of medical treatment, allowing us to alleviate symptoms, heal esophagitis and prevent complications in the majority of cases. Nevertheless, many patients do not respond, because acid does not play any pathogenetic role. Prokinetics and reflux inhibitors have the potential to control motor abnormalities, but the results of clinical trials are inconsistent. Antidepressant drugs are effective in specific subgroups of NERD patients with visceral hypersensitivity, but larger, controlled clinical studies are necessary. Protective drugs or medical devices have been recently adopted to reinforce mucosal resistance and preliminary trials have confirmed their efficacy either combined with or as add-on medication to PPIs in refractory patients.
引用
收藏
页码:1333 / 1343
页数:11
相关论文
共 126 条
[41]   Regurgitation Is Less Responsive to Acid Suppression Than Heartburn in Patients With Gastroesophageal Reflux Disease [J].
Kahrilas, Peter J. ;
Jonsson, Andreas ;
Denison, Hans ;
Wernersson, Boerje ;
Hughes, Nesta ;
Howden, Colin W. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2012, 10 (06) :612-619
[42]   Response of Regurgitation to Proton Pump Inhibitor Therapy in Clinical Trials of Gastroesophageal Reflux Disease [J].
Kahrilas, Peter J. ;
Howden, Colin W. ;
Hughes, Nesta .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (08) :1419-1425
[43]   Prucalopride: A Review of Its Use in the Management of Chronic Constipation [J].
Keating, Gillian M. .
DRUGS, 2013, 73 (17) :1935-1950
[44]   Prucalopride decreases esophageal acid exposure and accelerates gastric emptying in healthy subjects [J].
Kessing, B. F. ;
Smout, A. J. P. M. ;
Bennink, R. J. ;
Kraaijpoel, N. ;
Oors, J. M. ;
Bredenoord, A. J. .
NEUROGASTROENTEROLOGY AND MOTILITY, 2014, 26 (08) :1079-1086
[45]   RETRACTED: Medical treatments in the short term management of reflux oesophagitis (Review) (Retracted Article) [J].
Khan, Mostafizur ;
Santana, Jose ;
Donnellan, Clare ;
Preston, Cathryn ;
Moayyedi, Paul .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (02)
[46]   Visceral hypersensitivity in non-erosive reflux disease [J].
Knowles, C. H. ;
Aziz, Q. .
GUT, 2008, 57 (05) :674-683
[47]   An alginate-antacid formulation (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients [J].
Kwiatek, M. A. ;
Roman, S. ;
Fareeduddin, A. ;
Pandolfino, J. E. ;
Kahrilas, P. J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 34 (01) :59-66
[48]   Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis:: Metropole study results [J].
Lauritsen, K ;
Devière, J ;
Bigard, MA ;
Bayerdörffer, E ;
Mózsik, G ;
Murray, F ;
Kristjánsdóttir, S ;
Savarino, V ;
Vetvik, K ;
De Freitas, D ;
Orive, V ;
Rodrigo, L ;
Fried, M ;
Morris, J ;
Schneider, H ;
Eklund, S ;
Larkö, A .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (03) :333-341
[49]   Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification [J].
Lundell, LR ;
Dent, J ;
Bennett, JR ;
Blum, AL ;
Armstrong, D ;
Galmiche, JP ;
Johnson, F ;
Hongo, M ;
Richter, JE ;
Spechler, SJ ;
Tytgat, GNJ ;
Wallin, L .
GUT, 1999, 45 (02) :172-180
[50]   Gastro-oesophageal reflux is more prevalent in Western dyspeptics: a prospective comparison of British and South-East Asian patients with dyspepsia [J].
Mahadeva, S ;
Raman, MC ;
Ford, AC ;
Follows, M ;
Axon, ATR ;
Goh, KL ;
Moayyedi, P .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (12) :1483-1490